Abstract: A precision syringe includes a syringe barrel and plunger that has a base, an internal portion, and an external portion. The internal portion of the plunger extends longitudinally into the syringe barrel. The internal portion has a first end coupled to the base and a second end that is configured to push fluid out of and/or suction fluid into the syringe barrel. The external portion extends longitudinally along an outer surface of the syringe barrel. The external portion has a first end coupled to the base and a second end that is configured to receive an applied force that causes the plunger to move relative to the syringe barrel so that the second end of the internal portion is actuated through a portion of the syringe barrel (e.g., to dispense fluid from or suction fluid into the syringe barrel).

Abstract: There is described a platform device for use in forming an anastomosis and maintaining a desired curvature of a lumen in a desired shape during an anastomosis assistance period. The platform is formed from one or more bioabsorbable or biodegradable polymer filaments. There is also described a method for inserting a platform device for use in creation of an arteriovenous fistula by identifying a candidate artery and a candidate vein and dissecting the candidate vein. Next, inserting a platform device into the vein and creating a breach in the candidate artery at a desired angle and location. Next, introducing the platform device and vein into the candidate artery and forming the platform device into a curvature angle selected to minimize turbulent blood flow in an anastomosis formed by the vein and the artery. The platform may also be used to maintain potency of supply blood vessels and/or organ blood vessels or the lumens daring an organ transplant procedure.

Abstract: The present invention provides prodrugs and methods of use thereof.

Abstract: A system and methods for the delivery of oxygen through a body cavity of a subject using oxygen microbubbles. Through circulation of oxygen microbubbles through the body cavity, oxygen and carbon dioxide exchange may occur. Overall improvement in extending survival rate time during emergency situations caused by pulmonary or similar oxygen-intake restricting injury and/or failure may be achieved through use of the invented system and methods.

Abstract: Various liquid and semisolid lubricant compositions are provided, in particular lubricant compositions containing oil from the seeds of the Brassicaceae Orychophragmus violaceus, preferably those that have been esterified with one or more fatty acids such as palmitoleic acid, oleic acid, linoleic acid, lauric acid, palmitic acid, stearic acid, or a combination thereof. In various aspects, lubricant compositions are provided that include a petroleum or a synthetic base oil and about 40% or less by weight of a liquid lubricant composition containing oil from the seeds of the Brassicaceae Orychophragmus violaceus, preferably those that have been esterified with one or more fatty acids. In various aspects, semisolid lubricant composition are provided containing an emulsion of (i) a thickener and (ii) an oil from the seeds of the Brassicaceae Orychophragmus violaceus, preferably those that have been esterified with one or more fatty acids.

Abstract: A medication bottle includes an outer container wall, an inner container wall and a fluid, such as an aversive liquid, located between the walls. In another aspect, the fluid is located within separate compartments or channels located between the walls where the walls contact or are secured to each other. A further aspect provides a removeable cap including multiple sensors, at least one of which is a biometric sensor.

Abstract: An engineered payload-delivery system includes a target cell binding unit, covalently bound to a pore forming unit, and a payload portion adapted with a region capable of non-covalently binding to the pore forming unit. The pore forming unit is derived from a particular sub-serotype of Clostridium toxin, while the payload region is derived from a different sub-serotype of Clostridium toxin. The disclosed chimeric protein-based composition is capable of specifically delivering payload to neural cells.

Abstract: The present invention provides compositions and methods for the delivery of antivirals to a cell or subject.

Abstract: An intravascular cutting device described herein uses high-pressure water, saline, or other fluid to cut tissue and other materials including but not limited to calcified tissue, stents, stent grafts, and other devices. In some embodiments, the cutting device includes a working end that has a nozzle with a hole to allow the release of a high-pressure fluid jet. Opposite of the nozzle is a catch plate or deflector anvil that prevents the fluid jet from cutting healthy tissue. The device user will place the item to be cut between the nozzle and catch plate and then advance the device along the item to be cut as the fluid jet is activated, thus cutting the object as it advances.

Abstract: A number of improvements are provided relating to computer aided surgery. The improvement relates to both the methods used during computer aided surgery and the devices used during such procedures. Some of the improvement relate to controlling the selection of which data to display during a procedure and/or how the data is displayed to aid the surgeon. Other improvements relate to the structure of the tools used during a procedure and how the tools can be controlled automatically to improve the efficiency of the procedure. Still other improvements relate to methods of providing feedback during a procedure to improve either the efficiency or quality, or both, for a procedure.

Abstract: Provided herein are compounds and methods for modulating the NF?B pathway. More particularly, provided are inhibitors of the NF?B pathway and the uses of such inhibitors in regulating diseases and disorders, e.g., to treat cancer, autoimmune diseases, inflammatory diseases, diabetes, cardiovascular diseases, or neurological diseases.

Abstract: The embodiments disclosed herein relate to various medical device components, including components that can be incorporated into robotic and/or in vivo medical devices, and more specifically including end effectors that can be incorporated into such devices. Certain end effector embodiments include various vessel cautery devices that have rotational movement as well as cautery and cutting functions while maintaining a relatively compact structure. Other end effector embodiments include various end effector devices that have more than one end effector.

Abstract: The present invention is directed to an oral supplement including creatine hydrochloride, which has an aqueous solubility that is at least 15 times greater than creatine monohydrate, where the oral supplement drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.

Abstract: The embodiments disclosed herein relate to various medical device components, including components that can be incorporated into robotic and/or in vivo medical devices. Certain embodiments include various modular medical devices for in vivo medical procedures.

Abstract: A healthcare provider user interface for treatment option and authorization is disclosed herein. In embodiments, a healthcare provider device includes a display coupled to one or more processors. The display includes a graphical user interface comprising one or more input interface display pages and one or more output interface display pages. The one or more input interface display pages may include one or more input boxes configured to receive information including patient physiological information, insurance provider information, historical medication prescriptions, and one or more medical diagnoses. The one or more output interface display pages may include a medication list generated based on the received information and a prior authorization form configured to receive one or more prior authorization input fields.

Abstract: Three dimensional nanofiber structures are provided and methods of production thereof.

Abstract: Disclosed herein are inhibitors of the GGDPS enzyme, and methods for their use in treating or preventing diseases, such as multiple myeloma. The inhibitors described herein can include compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are described.

Abstract: In accordance with embodiments of this disclosure, a computational simulation platform comprises a computer-implemented method that includes: generating a three-dimensional (3D) reconstruction of a vessel lumen and a surface of the vessel lumen based on invasive or non-invasive imaging; generating a mesh of the 3D reconstructed vessel lumen and surface of the vessel lumen; assigning material properties to the 3D reconstructed surface of the vessel lumen; importing design and material properties of stents and balloons; generating a mesh of a stent and balloon; positioning the meshed stent and balloon within the mesh of the 3D reconstructed vessel lumen and surface of the vessel lumen; performing balloon pre-dilation, stenting and balloon post-dilation computational simulations with the mesh of the 3D reconstructed vessel lumen and surface of the vessel lumen; and assessing stent and vessel morphometric and biomechanical measures based on the computational simulations.

Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Abstract: A new and distinct interspecific hybrid Corylus plant named ‘OSU 541.147’ characterized by a vigorous, upright growth habit, the production of nuts with round kernels that fall free of the husk at maturity, and resistance to eastern filbert blight caused by the fungus Anisogramma anomala (Peck) E. Müller.